LENZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LENZ Therapeutics Inc is not a strong buy for a beginner, long-term investor at this time. While the stock has shown some positive pre-market movement and analysts maintain a Buy rating, the lack of strong proprietary trading signals, limited financial growth, and absence of significant catalysts suggest that the stock is better suited for a hold rather than an immediate buy.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 51.738, and moving averages are converging, showing no clear trend. Key support and resistance levels are S1: 9.115, Pivot: 9.612, R1: 10.108.
Analysts maintain a Buy rating despite lowering price targets. Pre-market price is up 3.22%, indicating short-term positive sentiment.
No recent news or significant trading trends from hedge funds or insiders. Financial performance shows no revenue growth YoY, and net income remains negative.
In Q4 2025, revenue was flat YoY at $1.588M. Net income improved YoY but remains negative at -$35.896M. EPS increased to -1.15, up 150% YoY. Gross margin is stable at 73.68%.
Analysts maintain a Buy rating but have lowered price targets significantly over the past months, citing slower product launch ramp and revised revenue forecasts.
